Author

T. Dangi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:mouse· 7 Research Focus:host-pathogen & immune response· 6 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

P. Penaloza-MacMaster· 7 shared S. Sanchez· 5 shared J. Class· 3 shared J. M. Richner· 3 shared B. Awakoaiye· 2 shared I. Koralnik· 2 shared J. Richner· 2 shared L. Visvabharathy· 2 shared

Activity by Year

2021-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

P. Penaloza-MacMaster

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Time-dependent enhancement of mRNA vaccines by 4-1BB costimulation

S. Sanchez, T. Dangi, B. Awakoaiye, N. Irani, S. Fourati, J. M. Richner, P. Penaloza-MacMaster

This study shows that administering 4-1BB costimulatory antibodies after 96 hours post-mRNA vaccination enhances CD8 T cell responses and protection against breakthrough infections.

bioRxiv · Mar 1, 2024 · PreprintImmunology

Replication-attenuated r3LCMV vectors potentiate tumor control via IFN-I

Y. R. Chung, B. Awakoaiye, T. Dangi, S. Fourati, P. Penaloza-MacMaster

This study shows that replication-attenuated r3LCMV vectors enhance tumor control and survival in multiple tumor models, including immunodeficient mice, through IFN-I signaling.

bioRxiv · Dec 8, 2023 · PreprintImmunology

Pre-existing immunity modulates responses to mRNA boosters

T. Dangi, S. Sanchez, M. H. Lew, L. Visvabharathy, J. M. Richner, I. Koralnik, P. Penaloza-MacMaster

The paper shows pre-existing immunity affects the effectiveness of mRNA vaccine boosters, with lower pre-existing antibodies leading to greater post-booster increases and updated vaccines being more effective in certain serostatus groups.

bioRxiv · Jun 27, 2022Immunology

Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2

T. Dangi, S. Sanchez, M. Park, J. Class, M. C. Richner, J. M. Richner, P. Penaloza-MacMaster

This study shows that nucleocapsid-specific antibodies can help control SARS-CoV-2 infection in mice, suggesting their potential inclusion in vaccines and monoclonal therapies.

bioRxiv · Mar 9, 2022 · PreprintImmunology

SARS coronavirus vaccines protect against different coronaviruses

T. Dangi, N. Palacio, S. Sanchez, J. Class, L. Visvabharathy, T. Ciucci, I. Koralnik, J. Richner, P. Penaloza-MacMaster

This study shows SARS-CoV-2 vaccines and prior coronavirus infections generate cross-reactive antibodies and T cell responses that provide protection against other coronaviruses in humans and mice.

bioRxiv · Jun 1, 2021 · PreprintImmunology

A SARS CoV-2 nucleocapsid vaccine protects against distal viral dissemination

J. Class, T. Dangi, J. Richner, P. Penaloza-MacMaster

This study shows that including the nucleocapsid antigen in SARS CoV-2 vaccines improves protection against viral spread to the brain.

bioRxiv · Apr 26, 2021 · PreprintImmunology

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

S. Sanchez, N. Palacio, T. Dangi, T. Ciucci, P. Penaloza-MacMaster

This study shows that reducing the priming dose of a SARS-CoV-2 vaccine can lead to stronger immune responses after boosting, suggesting potential benefits for vaccine distribution and design.

bioRxiv · Mar 31, 2021 · PreprintImmunology